Despite these achievements, current checkpoint blockade therapy has been successful for only a minority of patients and a subset of cancers indicating that different cancers use multiple and/or diverse mechanisms to suppress CD8 T cell cytotoxicity and evade anti-tumor immunity. The gene discussed is CD8A; the disease is cancer.